Comparison of clinical and demographic characteristics of patients with hepatocellular carcinoma in the training (Singapore) and validation (HK+Zurich) cohorts
| Variables | Training cohort (n=57) | Validation cohort (n=98) | p Value | |
| Sex, F/M | n (%) | 7/50 (12/88) | 21/77 (21/79) | NS* |
| Age, years | Median (range) | 59 (31–84) | 60 (20–83) | NS† |
| Race, Asian/European | n (%) | 57/0 (100/0) | 46/52 (47/53) | <0.0001* |
| Viral status, non-infected/HepB, C, D | n (%) | 12/43 (21/75) | 32/66 (33/67) | NS* |
| Grade, 1+2/3+4 | n (%) | 33/21 (58/37) | 61/24 (62/24) | NS*‡ |
| TMN staging, I/II+III+IV | n (%) | 34/23 (60/40) | 21/77 (21/79) | <0.0001* |
| α-Fetoprotein, ng/ml | Median (range) | 19 (1.5–>70 000) | 50 (1–468 600) | NS† |
| Tumour size, cm | Median (range) | 6 (0.7–23) | 5 (1.2–23.5) | NS† |
| Survival, years | Median (25th/75th %) | 3.94 (0.9/5.5) | 3.8 (1.6/7.8) | NS§ |